T-type calcium channels are inhibited by fluoxetine and its metabolite norfluoxetine

Molecular Pharmacology
Achraf TraboulsiePhilippe Lory

Abstract

Fluoxetine, a widely used antidepressant that primarily acts as a selective serotonin reuptake inhibitor, also inhibits various neuronal ion channels. Using the whole-cell patch-clamp technique, we have examined the effects of fluoxetine and norfluoxetine, its major active metabolite, on cloned low-voltage-activated T-type calcium channels (T channels) expressed in tsA 201 cells. Fluoxetine inhibited the three T channels Ca(V)3.1, Ca(V)3.2, and Ca(V)3.3 in a concentration-dependent manner (IC(50) = 14, 16, and 30 microM, respectively). Norfluoxetine was a more potent inhibitor than fluoxetine, especially on the Ca(V)3.3 T current (IC(50) = 5 microM). The fluoxetine block of T channels was voltage-dependent because it was significantly enhanced for T channels in the inactivated state. Fluoxetine caused a hyperpolarizing shift in steady-state inactivation, with a slower rate of recovery from the inactivated state. These results indicated a tighter binding of fluoxetine to the inactivated state than to the resting state of T channels, suggesting a more potent inhibition of T channels at physiological resting membrane potential. Indeed, fluoxetine and norfluoxetine at 1 microM strongly inhibited cloned T currents (approximately 50 ...Continue Reading

References

Mar 1, 1992·The American Journal of Emergency Medicine·D J BorysE P Krenzelok
Nov 17, 1994·The New England Journal of Medicine·L Gram
Mar 1, 1994·Clinical Pharmacokinetics·A C AltamuraM Percudani
Jan 1, 1993·The Journal of Neuropsychiatry and Clinical Neurosciences·C N KarsonR A Komoroski
Jan 1, 1996·Annual Review of Physiology·J R Huguenard
Mar 4, 1997·Proceedings of the National Academy of Sciences of the United States of America·J García-ColungaR Miledi
Aug 15, 1997·Neural Computation·M L Hines, N T Carnevale
Mar 23, 1999·Pflügers Archiv : European journal of physiology·N KlugbauerF Hofmann
Jan 29, 2000·Naunyn-Schmiedeberg's Archives of Pharmacology·P PacherP P Nánási
Feb 16, 2000·Pharmacology & Therapeutics·C Hiemke, S Härtter
Feb 29, 2000·The Journal of Biological Chemistry·A MonteilJ Nargeot
Apr 6, 2000·The Journal of Biological Chemistry·A MonteilJ Nargeot
Jan 24, 2002·The Journal of Pharmacology and Experimental Therapeutics·Dierk ThomasJohann Kiehn
Jun 25, 2002·Biophysical Journal·Juan Carlos GomoraEdward Perez-Reyes
Apr 10, 2003·British Journal of Pharmacology·Toru KobayashiKazutaka Ikeda
Dec 10, 2003·Neuroreport·Bok Hee ChoiSang June Hahn
Mar 6, 2004·Journal of Bioenergetics and Biomembranes·Anne Marie R Yunker
Jan 29, 2005·Proceedings of the National Academy of Sciences of the United States of America·Matthew P AndersonSusumu Tonegawa
Feb 3, 2005·British Journal of Pharmacology·Louise E KennardAlistair Mathie

❮ Previous
Next ❯

Citations

Apr 26, 2013·Naunyn-Schmiedeberg's Archives of Pharmacology·Yun Ju ChaeSang June Hahn
Sep 6, 2012·Epilepsia·Kajsa M Igelström, Philip M Heyward
Sep 3, 2010·The Journal of Neuroscience : the Official Journal of the Society for Neuroscience·Yuguo YuDavid McCormick
Feb 25, 2014·Pflügers Archiv : European journal of physiology·Benjamin J KopeckyJianxin Bao
Dec 11, 2007·Canadian Journal of Physiology and Pharmacology·C BoselliA Lucchelli
Jun 13, 2009·Cellular and Molecular Life Sciences : CMLS·Cristina LanniCinzia Boselli
Nov 23, 2010·Expert Opinion on Therapeutic Patents·Fabrizio GiordanettoAndreas Wållberg
Nov 4, 2006·The Journal of Physiology·Achraf TraboulsiePhilippe Lory
Sep 29, 2009·European Journal of Pharmacology·Kee-Hyun Choi, Hyewhon Rhim
Jul 6, 2007·Neuropharmacology·Richard L KrausJohn J Renger
Nov 14, 2012·British Journal of Pharmacology·L CardamoneN C Jones
May 19, 2010·Journal of Neurochemistry·Andreas Wolfram HenkelJohannes Kornhuber
Oct 5, 2010·American Journal of Medical Genetics. Part B, Neuropsychiatric Genetics : the Official Publication of the International Society of Psychiatric Genetics·Francesco CasamassimaRoy H Perlis
Jun 14, 2008·Chemico-biological Interactions·Christelle BertrandArnaud Chatonnet
Jan 30, 2015·Pflügers Archiv : European journal of physiology·Hyun Jong KimMin Goo Lee
Mar 27, 2015·Annals of the New York Academy of Sciences·Andrew F LeuchterIan A Cook
May 1, 2007·Expert Opinion on Therapeutic Targets·Philippe Lory, Jean Chemin
May 24, 2011·Journal of Affective Disorders·Konstantinos N FountoulakisHagop Akiskal
Mar 29, 2014·Frontiers in Behavioral Neuroscience·Giuseppe GangarossaEmmanuel Valjent
Jan 7, 2009·Therapeutic Advances in Cardiovascular Disease·Michela SalaPaolo Brambilla
Jun 6, 2019·American Journal of Physiology. Cell Physiology·Rachel A FischerRebecca M Sappington
Aug 5, 2010·The Journal of Pharmacology and Experimental Therapeutics·Richard L KrausJohn J Renger
Oct 27, 2017·PloS One·Chaymae El AlaouiPhilippe Lory
Sep 1, 2017·Restorative Neurology and Neuroscience·Yefei SunChuansheng Zhao
Sep 22, 2009·Environmental Science & Technology·Judith NeuwoehnerBeate I Escher
Jun 29, 2021·Frontiers in Neuroscience·Paula P PerissinottiErika S Piedras-Rentería
Sep 7, 2021·Human Reproduction·Rita RahbanSerge Nef

❮ Previous
Next ❯

Related Concepts

Trending Feeds

COVID-19

Coronaviruses encompass a large family of viruses that cause the common cold as well as more serious diseases, such as the ongoing outbreak of coronavirus disease 2019 (COVID-19; formally known as 2019-nCoV). Coronaviruses can spread from animals to humans; symptoms include fever, cough, shortness of breath, and breathing difficulties; in more severe cases, infection can lead to death. This feed covers recent research on COVID-19.

Blastomycosis

Blastomycosis fungal infections spread through inhaling Blastomyces dermatitidis spores. Discover the latest research on blastomycosis fungal infections here.

Nuclear Pore Complex in ALS/FTD

Alterations in nucleocytoplasmic transport, controlled by the nuclear pore complex, may be involved in the pathomechanism underlying multiple neurodegenerative diseases including Amyotrophic Lateral Sclerosis and Frontotemporal Dementia. Here is the latest research on the nuclear pore complex in ALS and FTD.

Applications of Molecular Barcoding

The concept of molecular barcoding is that each original DNA or RNA molecule is attached to a unique sequence barcode. Sequence reads having different barcodes represent different original molecules, while sequence reads having the same barcode are results of PCR duplication from one original molecule. Discover the latest research on molecular barcoding here.

Chronic Fatigue Syndrome

Chronic fatigue syndrome is a disease characterized by unexplained disabling fatigue; the pathology of which is incompletely understood. Discover the latest research on chronic fatigue syndrome here.

Evolution of Pluripotency

Pluripotency refers to the ability of a cell to develop into three primary germ cell layers of the embryo. This feed focuses on the mechanisms that underlie the evolution of pluripotency. Here is the latest research.

Position Effect Variegation

Position Effect Variagation occurs when a gene is inactivated due to its positioning near heterochromatic regions within a chromosome. Discover the latest research on Position Effect Variagation here.

STING Receptor Agonists

Stimulator of IFN genes (STING) are a group of transmembrane proteins that are involved in the induction of type I interferon that is important in the innate immune response. The stimulation of STING has been an active area of research in the treatment of cancer and infectious diseases. Here is the latest research on STING receptor agonists.

Microbicide

Microbicides are products that can be applied to vaginal or rectal mucosal surfaces with the goal of preventing, or at least significantly reducing, the transmission of sexually transmitted infections. Here is the latest research on microbicides.